Research from industry analyst GlobalData finds that Chinese companies are leading in the development of antibody-drug conjugates (ADC).
A rapidly growing therapeutic class, ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, with the two being connected via a linker.
This approach is used to selectively target and eliminate cancerous cells, and has the potential to significantly improve cancer outcomes, scientists believe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze